Karyopharm Therapeutics Inc. (NASDAQ:KPTI) went down by -3.56% from its latest closing price compared to the recent 1-year high of $14.73. The company’s stock price has collected -1.52% of loss in the last five trading sessions.
Is It Worth Investing in Karyopharm Therapeutics Inc. (NASDAQ :KPTI) Right Now?
Plus, the 36-month beta value for KPTI is at -0.04. Opinions of the stock are interesting as 4 analysts out of 10 who provided ratings for Karyopharm Therapeutics Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $8.80, which is $5.55 above the current price. KPTI currently public float of 74.06M and currently shorts hold a 28.23% ratio of that float. Today, the average trading volume of KPTI was 2.69M shares.
KPTI’s Market Performance
KPTI stocks went down by -1.52% for the week, with a monthly jump of 7.62% and a quarterly performance of -26.64%, while its annual performance rate touched -57.96%. The volatility ratio for the week stands at 8.83% while the volatility levels for the past 30 days are set at 11.22% for Karyopharm Therapeutics Inc. The simple moving average for the period of the last 20 days is 5.71% for KPTI stocks with a simple moving average of -35.90% for the last 200 days.
Analysts’ Opinion of KPTI
Many brokerage firms have already submitted their reports for KPTI stocks, with Piper Sandler repeating the rating for KPTI by listing it as a “Overweight.” The predicted price for KPTI in the upcoming period, according to Piper Sandler is $8 based on the research report published on January 19th of the current year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see KPTI reach a price target of $10, previously predicting the price at $7. The rating they have provided for KPTI stocks is “Outperform” according to the report published on November 04th, 2022.
JP Morgan gave a rating of “Neutral” to KPTI, setting the target price at $8 in the report published on February 09th of the previous year.
KPTI Trading at -19.74% from the 50-Day Moving Average
After a stumble in the market that brought KPTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.94% of loss for the given period.
Volatility was left at 11.22%, however, over the last 30 days, the volatility rate increased by 8.83%, as shares surge +7.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.25% lower at present.
During the last 5 trading sessions, KPTI fell by -1.52%, which changed the moving average for the period of 200-days by -59.98% in comparison to the 20-day moving average, which settled at $3.09. In addition, Karyopharm Therapeutics Inc. saw -4.41% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at KPTI starting from Paulson Richard A., who sale 3,922 shares at the price of $3.27 back on Jan 04. After this action, Paulson Richard A. now owns 608,605 shares of Karyopharm Therapeutics Inc., valued at $12,825 using the latest closing price.
Paulson Richard A., the President and CEO of Karyopharm Therapeutics Inc., sale 3,490 shares at $5.17 during a trade that took place back on Dec 05, which means that Paulson Richard A. is holding 612,527 shares at $18,043 based on the most recent closing price.
Stock Fundamentals for KPTI
Current profitability levels for the company are sitting at:
- -43.33 for the present operating margin
- +98.00 for the gross margin
The net margin for Karyopharm Therapeutics Inc. stands at -59.14. Equity return is now at value 84.00, with -32.40 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.74.